RUSSIAN BIOPHARMACEUTICAL COMPANY TO CONSOLIDATE NATION'S LEADING BIOFACTORIES

Russia consolidates top biofactories into state-owned biotech giant by 2026

A major Russian biopharmaceutical company will bring together the country's top biofactories to develop new veterinary drugs, including vaccines against highly dangerous diseases, TASS reports, citing the Russian Ministry of Agriculture.

The initiative, launched under a presidential decree, aims to ensure technological sovereignty and sustainable growth in the sector.

In a statement, the ministry emphasized that the consolidation will bolster Russia's technological independence, stimulate investment in veterinary science, and strengthen the domestic biotech industry.

"This is a critical step toward enhancing biological security and expanding our own technological capabilities," the ministry noted.

The new entity, established under a July 2025 presidential order, will integrate the Shchyolkovo Biocombinate, as well as the biofactories in Armavir, Kursk, Oryol, and Stavropol. The move is expected to pool industrial and research expertise, accelerating the development of innovative solutions for the industry.

Key objectives of the consolidated structure include advancing biotechnology, producing veterinary medications, and conducting research. Particular focus will be placed on anti-epizootic measures, including the development of vaccines against high-risk diseases.

Oleg Akinin, director of the Shchyolkovo Biocombinate, highlighted the rapid pace and fierce competition in the veterinary drug market.

"Above all, this drives market players to continuously improve efficiency, respond swiftly to external changes, and prioritize high-tech, science-intensive products that meet consumer demand," he explained.

Earlier, on March 30, 2026, Russian President Vladimir Putin signed a decree establishing the joint-stock company Russian Biological Industrial Company, with all shares to remain in federal ownership.